Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels.
Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in …

Remarkable progress has been made in the development of biomarker-driven targeted
therapies for patients with multiple cancer types, including melanoma, breast and lung …

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Colon Cancer focuses on systemic therapy options for the treatment of metastatic …

Background Patients with metastatic colorectal cancer with the BRAF V600E mutation have
a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial …

This portion of the NCCN Guidelines for Colon Cancer focuses on the use of systemic
therapy in metastatic disease. Considerations for treatment selection among 32 different …

The number of molecularly stratified treatment options available to patients with colorectal
cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide …

The development of noninvasive methods to detect and monitor tumors continues to be a
major challenge in oncology. We used digital polymerase chain reaction–based …

Background Patients with metastatic colorectal cancer that harbors KRAS mutations in exon
2 do not benefit from anti–epidermal growth factor receptor (EGFR) therapy. Other activating …

KRAS is the most frequently mutated oncogene in cancer and KRAS mutation is commonly
associated with poor prognosis and resistance to therapy. Since the KRAS oncoprotein is …

Colorectal cancer (CRC) is a leading cause of death among cancer patients. This
heterogeneous disease is characterized by alterations in multiple molecular pathways …